TMCnet News
Growing Adoption of Combination Therapies Driving the Global Chronic Obstructive Pulmonary Disease Drugs Market Until 2020, Says TechnavioAccording to the latest market study released by Technavio, the global chronic obstructive pulmonary disease (COPD) drugs market is expected to grow at a CAGR of close to 5% during the forecast period. This research report titled 'Global COPD Drugs Market 2016-2020' provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions. Request sample report: http://goo.gl/STz9To The report categorizes the global COPD drugs market into three major drugs class segments. They are:
Global combination therapies market The combination therapies segment accounted for a market share of over 48% in the global COPD drugs market in 2015 and is expected to maintain its dominant position in the market during the forecast period. Combination drugs consisting of LABA/ICS (inhaled corticosteroid) are becoming a therapeutic trend in the market due to their effectiveness, thereby, increasing patient compliance. The market is set to witness the launch of many such therapies during the forecast period. LABA, including beta-sympathomimetics used for bronchodilation, and ICS, a corticosteroid used for inhalation, are among such therapies. These drugs suppress the immune response in individuals with asthma and reduce bronchial hyperactivity. Advair/Seretide/Adoair by GSK is the leading drug in this category. Apart from this, a combination of SABA/SAMA is also used to treat COPD. Drugs under this category include a combination of albuterol and ipratropium (Combivent). According to Barath Palada, a lead rare diseases analyst from Technavio, "The market for combination therapies to treat COPD is expected to grow at a fast pace during the forecast period, owing to the efficacy of these drugs over monotherapies. Also, around 25% of the drugs present in the pipeline are combination therapies, and a few of them are expected to be launched during the forecast period." Global bronchodilators market The bronchodilators markt in the global COPD drugs market was valued at USD 2.91 billion in 2015 and is likely to reach USD 3.41 billion by 2020, growing at a CAGR of above 3%. After the combination therapies, bronchodilators dominate the COPD drugs market, occupying a share of approximately 23%. The pipeline products available include bronchodilators or a combination of these drugs. These drugs are expected to grow at a moderate pace during the forecast period. Many short-acting bronchodilators act as rescue medications for COPD due to their rapid onset of action. Bronchodilators help relax the bronchial muscles, making the air passage through the lungs easy, thereby resulting in normal breathing. These drugs can be categorized into three types:
Global steroids market The services segment is the third largest segment in the market, growing at a CAGR of more than 2% and is expected to reach USD 1.75 billion by 2020. Steroid drugs market is growing at a slow pace as they are not used in too many cases. These drugs are used mostly in combination with bronchodilators to treat COPD, and are mostly used for a long-term basis. The reason for the slow growth can be attributed to the switch in medications for inhaled corticosteroids to combination therapies or more efficacious bronchodilators and PDE-4 inhibitors. "Steroids are mainly used to reduce the swelling and inflammation of the airway passages. They can be either inhaled or taken orally. The action shown by them is very slow, and it may take days for the benefits to be noticed. These drugs can also be used in combination with bronchodilators," adds Barath. Steroids are usually associated with side effects and must be taken under the supervision of a licensed physician. Some corticosteroids used by the inhalation route are fluticasone inhaled (Flovent), and budesonide inhaled (Pulmicort, Pulmicort, and Flexhaler), and those administered by the oral route are prednisone (Rayos) and methylprednisolone (Solu-Medrol, Medrol, and A-Methapred). The top vendors highlighted by Technavio's healthcare and life sciences research analysts in this report are:
Browse Related Reports:
Do you need a report on a market in a specific geographical cluster or country but can't find what you're looking for? Don't worry, Technavio also takes client requests. Please contact [email protected] with your requirements and our analysts will be happy to create a customized report just for you. About Technavio Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at [email protected].
View source version on businesswire.com: http://www.businesswire.com/news/home/20160725005408/en/ |
